Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
CAR T-cell therapy
|
| gptkbp:administrativeDivision |
pre-treatment lymphodepletion
|
| gptkbp:approves |
gptkb:European_Union
gptkb:United_States large B-cell lymphoma |
| gptkbp:clinicalTrials |
Phase 2
high response rates ZUMA-1 |
| gptkbp:contraindication |
fatigue
headache nausea fever confusion seizures chills active infections hypotension tachycardia dyspnea severe comorbidities |
| gptkbp:developedBy |
gptkb:Gilead_Sciences
|
| gptkbp:dosageForm |
cell suspension
|
| gptkbp:firstAppearance |
October 2017
|
| gptkbp:hasCapacity |
educational resources
support groups financial assistance programs nurse navigation services |
| gptkbp:hasPopulation |
adults
|
| gptkbp:healthcare |
CD19 positive malignancies
|
| gptkbp:historicalResearch |
combination therapies
long-term outcomes biomarker_studies |
| https://www.w3.org/2000/01/rdf-schema#label |
Yescarta
|
| gptkbp:impact |
blood tests
vital signs single infusion neurological assessments overall survival benefit infection signs cytokine levels |
| gptkbp:is_used_in |
potential for durable remission
|
| gptkbp:mandates |
relapsed or refractory large B-cell lymphoma
|
| gptkbp:marketedAs |
brand name
|
| gptkbp:offers |
approximately $373,000
|
| gptkbp:productionCompany |
ex vivo T cell activation
|
| gptkbp:regulatoryCompliance |
FDA_approved
EMA_approved |
| gptkbp:relatedPatent |
Breyanzi
Kymriah |
| gptkbp:research |
non-profit organizations
government grants pharmaceutical companies clinical research organizations |
| gptkbp:researchFocus |
hematologic malignancies
|
| gptkbp:route |
intravenous
|
| gptkbp:runnerUp |
monitoring for side effects
|
| gptkbp:setting |
outpatient
|
| gptkbp:sideEffect |
cytokine release syndrome
neurological toxicities |
| gptkbp:storage |
frozen
|
| gptkbp:triggerType |
genetically modified T cells
|
| gptkbp:type |
immunotherapy
|